FDA Approves Apretude
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders...
December 27, 2021
by Drugs
FDA approves ViiV Healthcare’s Apretude for HIV prevention
The long-acting injectable is indicated for use in adults and adolescents who are at risk of sexually acquiring HIV and test negative for HIV-1 before initiation.
December 22, 2021
by Pharmaceutical-Business-Review
US FDA approves ViiV Healthcare’s Cabenuva as complete long-acting regimen for HIV treatment
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year.
January 22, 2021
by expresspharma
European Commission approves dispersible tablets to treat paediatric HIV
Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
January 14, 2021
by europeanpharmaceuticalreview
First long-acting HIV treatment approved in Europe
The European Commission approval of the long-acting injectable HIV treatment could transform the lives of people living with the disease.
January 5, 2021
by europeanpharmaceuticalreview
EU nod for first long-acting HIV injectable treatment
The European Commission (EC) has authorised Janssen’s Rekambys (rilpivirine injection) in combination with ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) to treat HIV-1 infections in adults who are virologically suppressed.
December 22, 2020
by pharmatimes
ViiV’s cabotegravir scores breakthrough designation for HIV prevention
GlaxoSmithKline subsidiary ViiV Healthcare has announced that its long-acting injectable cabotegravir has scored a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for HIV prevention.
November 19, 2020
by pharmatimes
ViiV’s long-acting HIV drug beats standard of care in prevention study
ViiV Healthcare has announced that its long-acting injectable cabotegravir for HIV prevention demonstrated superiority compared to the current standard of treatment for women.
November 12, 2020
by pharmatimes
ViiV’s two-drug HIV regimen demonstrates long-term efficacy
ViiV Healthcare has released long-term data for its two-drug regimen of dolutegravir plus lamivudine, which continued to offer non-inferior efficacy compared to a three-drug regimen in HIV.
October 10, 2020
by pharmatimes
ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato
Specialist HIV company ViiV Healthcare has secured approval from the US Food and Drug Administration (FDA) for its Dovato (dolutegravir/lamivudine) as a complete regimen to treat HIV-1 infection.
August 11, 2020
by pharmaceutical-business-review
FDA approves ViiV's novel HIV treatment Rukobia
The US Food and Drug Administration (FDA) has approved ViiV Healthcare's novel attachment inhibitor Rukobia (fostemsavir) expanding treatment options for HIV.
July 3, 2020
by pharmatimes
ViiV selects projects for HIV/COVID-19 response fund
ViiV Healthcare has announced that 109 projects from 26 countries are to get financial support from its Global HIV and COVID-19 Emergency Response Fund.
July 2, 2020
by pharmatimes